EGFR and non-small cell lung carcinoma: The pretreatment with miR-145 reduced tumor growth by suppressing the expression of EGFR induced cell arrest of the G1/S cycle phase, and improved the sensitivity of A549, NSCLC cell line, to erlotinib [7,83,84].